Amgen Inc. v. Xavier Becerra
This text of Amgen Inc. v. Xavier Becerra (Amgen Inc. v. Xavier Becerra) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
AMGEN INC., et al.,
Plaintiffs, v. Civil Action No. 24-3571 (JEB)
ROBERT F. KENNEDY, JR., et al.,
Defendants.
MEMORANDUM OPINION AND ORDER
Plaintiffs Amgen, Eli Lilly, and UCB sell prescription medication. See ECF No. 1
(Compl.), ¶ 4. In 2024, they brought this lawsuit to challenge the Government’s implementation
of Section 340B of the Public Health Service Act, which requires pharmaceutical companies to
sell their drugs at discounted rates to certain healthcare providers, including government-funded
clinics that treat sexually transmitted diseases. Id., ¶¶ 19–26. Only providers that meet Section
340B’s requirements can make use of these discounts, and covered entities must get certified and
periodically recertified as eligible by the Secretary of Health and Human Services. See 42
U.S.C. § 256b(a)(7). Plaintiffs contend that the Secretary, along with the Health Resources and
Services Administration (HRSA), the HHS department that administers Section 340B, have
shirked their duties — certifying ineligible providers as qualifying STD clinics and thereby
costing Plaintiffs millions in unwarranted discounts. See Compl., ¶¶ 28–34. Plaintiffs challenge
the legality of the Government’s overall certification process, as well as the specific certification
of one healthcare entity, Sagebrush Health Services, and its nine subdivisions. Id. at 41–43.
1 Community Care Resources of Florida (CCRF), one of the certified STD clinics
receiving discounted medicine under Section 340B, but not one of the providers Plaintiffs seek to
decertify, now moves to intervene as a defendant. See ECF No. 27 (Mot.) at 1. It asks to join
the lawsuit to “defend . . . the certification and recertification process” and to “represent[] the
interests of the STD clinics that HHS certifies.” Id. Plaintiffs oppose the Motion, arguing that
CCRF’s intervention would be improper. See ECF No. 29 (Opp.) at 1. The Court will grant the
Motion.
I. Legal Standard
Federal Rule of Civil Procedure 24 details two forms of intervention: intervention as of
right and permissive intervention. Under Rule 24(a)(2), courts must permit intervention when an
intervenor “claims an interest relating to the . . . transaction that is the subject of the action, and
is so situated that disposing of the action may as a practical matter impair or impede the
movant’s ability to protect its interest, unless existing parties adequately represent that interest.”
See also Bldg. and Const. Trades Dep’t, AFL-CIO v. Reich, 40 F.3d 1275, 1282 (D.C. Cir.
1994). Rule 24(b), conversely, allows courts to grant intervention where the intervenor “has a
claim or defense that shares with the main action a common question of law or fact.” Fed. R.
Civ. P. 24(b). Courts have “wide latitude” in exercising their discretion over permissive
intervention. EEOC v. Nat’l Child.’s Ctr., Inc., 146 F.3d 1042, 1046 (D.C. Cir. 1998). In doing
so, however, “the court must consider whether the intervention will unduly delay or prejudice the
adjudication of the original parties’ rights.” Fed. R. Civ. P. 24(b).
Our Circuit has at times described the need for intervenor-defendants to show Article III
standing, even though standing is a hurdle typically reserved for plaintiffs — i.e., the parties
seeking to invoke a court’s jurisdiction. Crossroads Grassroots Pol’y Strategies v. Fed. Election
2 Comm’n, 788 F.3d 312, 316 (D.C. Cir. 2015) (“[W]here a party tries to intervene as another
defendant, we have required it to demonstrate Article III standing.”); Yocha Dehe v. U.S. Dep’t
of the Interior, 3 F.4th 427, 431–32 (D.C. Cir. 2021) (“Because [intervenor-defendant] does not
currently satisfy the injury requirement of Article III standing, it lacks standing to intervene.”).
Such a showing is unnecessary, however, when the intervenor-defendant “seek[s] the same relief
sought by at least one existing party.” Institutional S’holder Servs., Inc. v. Sec. & Exch.
Comm’n, 142 F.4th 757, 764 n.3 (D.C. Cir. 2025) (citing Little Sisters of the Poor Saints Peter &
Paul Home v. Pennsylvania, 591 U.S. 657, 674 n.6 (2020)).
II. Analysis
Although CCRF may be able to intervene here as a matter of right, the Court need not so
decide because it will grant permissive intervention.
To begin, CCRF seeks the same outcome as Defendants — the Court’s upholding of
HRSA’s Section 340B certification procedures, see Mot. at 1 — so a standing analysis is
unnecessary. As for Rule 24(b)’s requirements, the Court finds that CCRF’s proposed defense
shares a common question of law with the main action. Plaintiffs challenge, among other things,
the Government’s Section 340B certification process, see Compl. at 41, under which CCRF was
previously certified and will presumably pursue recertification. For that reason, CCRF plans to
argue, like Defendants, that the certification process is in accordance with the law. See Mot. at
27. This shared defense suffices to show a common question of law with the main action. Sault
Ste. Marie Tribe of Chippewa Indians v. Bernhardt, 331 F.R.D. 5, 14 (D.D.C. 2019) (“That
[intervenors] share this defense in common with the [Defendant] is sufficient under Rule
24(b)(1)(B).”).
3 Further, the Court finds that CCRF’s Motion is timely. Courts in this district review
timeliness “in consideration of all the circumstances, especially weighing the factors of time
elapsed since the inception of the suit, the purpose for which intervention is sought, the need for
intervention as a means of preserving the applicant’s rights, and the probability of prejudice to
those already parties in the case.” Amador Cnty. v. U.S. Dep’t of Interior, 772 F.3d 901, 903
(D.C. Cir. 2014) (quoting United States v. British Am. Tobacco, 437 F.3d 1235, 1238 (D.C. Cir.
2006)). Plaintiffs take issue with the fact that CCRF’s Motion came in nearly a year after they
initiated this lawsuit. See Opp. at 10. Time elapsed, however, does not alone render a motion
untimely in the absence of any prejudice to the parties. Roane v. Leonhart, 741 F.3d 147, 151
(D.C. Cir. 2014). Here, briefing on the competing Motions for Summary Judgment has not yet
begun, and CCRF has attested that it is “prepared to comply with all scheduling orders.” Mot. at
25. In addition, despite Plaintiffs’ worry that CCRF will complicate proceedings by putting its
own certification at issue, see Opp.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
Amgen Inc. v. Xavier Becerra, Counsel Stack Legal Research, https://law.counselstack.com/opinion/amgen-inc-v-xavier-becerra-dcd-2026.